Quick Answer
TScan Therapeutics, Inc. reported Cash and Equivalents of $152.41 million for fiscal year 2025.
TScan Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $152.41M | -14.7% |
| 2024 | $178.69M | +34.0% |
| 2023 | $133.36M | +11.1% |
| 2022 | $120.03M | -25.6% |
| 2021 | $161.41M | +363.9% |
| 2020 | $34.79M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $169.51M | +27.3% | +0.1% |
| June 30, 2025 | $169.39M | -30.0% | +9.9% |
| March 31, 2025 | $154.11M | +9.7% | -13.8% |
| December 31, 2024 | $178.69M | +34.0% | +34.2% |
| September 30, 2024 | $133.12M | -14.2% | -45.0% |
| June 30, 2024 | $242.16M | +16.0% | +72.3% |
| March 31, 2024 | $140.51M | +47.0% | +5.4% |
| December 31, 2023 | $133.36M | +11.1% | -14.1% |
- TScan Therapeutics, Inc. showed a decrease of -14.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s cash and equivalents has grown by 338.1% (from $34.79 million to $152.41 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: